John Baird, M.D.

Hematology
Medical Oncology
Internal Medicine
2013, M.D., University of Arkansas for Medical Sciences, Little Rock, AR
2008, B.S., Biomedical Engineering, Washington University, St. Louis, MO
2020-2021, Fellow, Blood and Marrow Transplantation, Stanford Hospital & Clinics, Palo Alto, CA
2019-2020, Postdoctoral Fellow, Cancer Cellular Therapies, Stanford University, Palo Alto, CA
2016-2019, Fellow, Hematology and Medical Oncology, Stanford Hospital & Clinics, Palo Alto, CA
2014-2016, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
2013-2014, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
2021-resent, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2020, Abstract Achievement Award, American Society of Hematology
2019, NIH T32 Institutional Training Grant, Stanford, Department of BMT
2013, Richard V. Ebert Award, UAMS, Department of Internal Medicine
2013, Graduated with Honors in Research, UAMS
2012, Class of 1949 Scholarship, UAMS
2012, Clinical Research Training Program Fellow, NIH-OCRTME
2011, Alpha Omega Alpha, UAMS
2010, Barton Foundation Scholarship, UAMS
2010, Dr. George S. Wise Memorial Scholarship, UAMS
2009, Class of 1954 Scholarship, UAMS
2009, Medical Student Research Program in Diabetes, NIDDK
2008, Medical Alumni Association Scholarship, UAMS
2008, Dorothy Snider Foundation Scholarship, UAMS
2003, Eagle Scout, Bronze and Gold Eagle Palms, BSA QAC Troop 7
American Society for Transplantation and Cellular Therapy
American Society of Hematology, Associate Member
American Society of Clinical Oncology
CIBMTR Infection and Immune Reconstitution Working Group
American College of Physicians
- Baird JH, Frank MJ, Craig J, et al.: “CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.” Blood. 2021; doi: 10.1182/blood.2020009432.
- Spiegel JY, Patel S, Muffly L, Hossain N, Oak J, Baird JH, et al.: “Dual targeting CD19/CD22 chimeric antigen receptor T cells in adults with recurrent or refractory B cell malignancies.” Nat Med. 2020 in submission.
- Johnsrud AJ, Craig J, Baird JH, et al. “Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T cell therapy.” Blood Adv. 2021; doi: 10.1182/bloodadvances.2021004716.
- Baird JH, Epstein DJ, Tamaresis JS, et al.: “Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.” Blood Adv. 2021; 5(1):143-55.
- Van Vuren AJ, Minniti CP, Mendelsohn L, Baird JH, et al.: “Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in SCD.” Am J
- Baird JH, Gotlib J, George TI, et al.: “A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.” Blood Adv. 2019 Aug 13;3(15):2264-2271.
- Baird JH, Gotlib J: “Clinical validation of KIT inhibition in advanced systemic mastocytosis.” Curr Hematol Malig Rep. 2018 Oct;13(5):407-416.
- Baird JH, Minniti CP, Lee JM, Tian X, et al.: “Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.” Br. J. Haematol. 2015; 168(5):737-46. 7.
- Baird JH, Frey N, Birnbaum B, Porter DL: “Voriconazole-induced periostitis after allogeneic stem cell transplantation.” Am. J. Hematol. 2015; 90(6):574-5.
- Lodhi IJ, Yin L, Coleman T, Baird JH, et al.: “Targeted inhibition of adipose lipogenesis decreases obesity and insulin resistance by disrupting PPAR-γ activation.” Cell Metab. 2012; 16(2):189-201.